UnannouncedVCRaise

Filed before 2025Filed 11 October 2022

Elysium Therapeutics, Inc. has sold $2.23M so far

Elysium Therapeutics, Inc., a biotech company based in Akron, OH, has sold $2.23M so far in its equity round, according to a filing dated 11 October 2022.

Raises filed before 2025 are not checked for a public announcement.

Filed
11 October 2022
First filed
16 November 2020
Round
Equity round (amended filing)
Amount sold
$2.23M
Offering size
$9.13M
Investors so far
30
Based in
Akron, OH

Investors on the board

Firms come from the venture funds whose filings name a director of this company.

Who is on the board

1 director of this company is named on venture funds' filings. Sign in free with Google to see who, the full filing, and a short list of rounds like this each morning.

Sign in with Google

How it compares

Larger than 16% of the 1,764 tracked raises with an amount filed in 2022, and than 14% of the 142 in biotech.

Elysium Therapeutics, Inc. in public filings

FiledFilingSoldRaise
11 Oct 2022Amended filing$2.23MThis raise
16 Nov 2020New filing$915KThis raise

Everything on Elysium Therapeutics, Inc.

More with Mesa Verde on the board

  1. MatriSys Bioscience, Inc.$8.4MFiled before 202527 Jul 2022 · La Jolla, CA
  2. ViaCyte Inc.$53.9MFiled before 202522 Apr 2021 · San Diego, CA
  3. AltheaDx, Inc.$3.73MFiled before 20259 Dec 2020 · San Diego, CA
  4. HCW Biologics Inc.$6.17MFiled before 202519 Oct 2020 · Miramar, FL

All 28 raises

Other unannounced rounds

  1. DVx Atomic Co.$18.5MUnannounced · 1 day16 Sep 2026 · Boston, MA
  2. Aperio Systems, Inc.$1.6MUnannounced · 1 day16 Sep 2026 · Boston, MA
  3. Twin Health, Inc.$59MUnannounced · 1 day16 Sep 2026 · Menlo Park, CA
  4. Scoring Factory AI Inc.$500KUnannounced · 2 days15 Sep 2026 · New York, NY
  5. Royal & Pelham, Inc.$5.4MUnannounced · 2 days15 Sep 2026 · New Orleans, LA
  6. SPECTRA Holdings US, Ltd.$2.5MUnannounced · 2 days15 Sep 2026 · Sandy Springs, GA

All unannounced rounds

Seen it announced?

Send the link and the check will look at it.